AUF1 is upregulated by angiotensin II to destabilize cardiac Kv4.3 channel mRNA.
Expression of cardiac myocyte Kv4 channels (Kv4.3 for human, Kv4.2 and Kv4.3 for rodents) is downregulated with hypertrophy in vivo leading to a decrease in the transient outward current (Ito). This effect is recapitulated in vitro with rat neonatal cardiac myocytes treated with angiotensin II (Ang II), which acts via AT(1) receptors, NADPH oxidase and p38 MAP kinase to destabilize the 3' untranslated region (3'UTR) of the Kv4.3 channel messenger RNA (mRNA). Here deletion analysis and mutagenesis identify an AU-rich element (ARE) in the Kv4.3 3'UTR that is required for Ang II-induced destabilization. Overexpression of AUF1 (ARE/poly-(U)-binding/degradation factor 1), an RNA destabilizing protein, mimics and occludes the Ang II effect, while RNA interference targeted against AUF1 blocks the Ang II effect on the Kv4.3 3'UTR. Ang II upregulates AUF1 by activating AT(1) receptors, NADPH oxidase and p38 MAP kinase. Finally, pull-down assays establish that Ang II increases AUF1 binding to the ARE required for destabilization, while binding of the mRNA stabilizing protein HuR is unaffected. Hence, Ang II acts via AT(1) receptors, NADPH oxidase and p38 MAP kinase to upregulate AUF1, which in turn binds to an ARE in the Kv4.3 3'UTR to destabilize the channel mRNA.
Zhou
Chaoming
C
Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Vignere
Chandra Z
CZ
Levitan
Edwin S
ES
D020413:3' Untranslated Regions / Q000235:genetics / Q000378:metabolism*; D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D001483:Base Sequence / Q000235:genetics; D002478:Cells, Cultured; D000081035:Heterogeneous Nuclear Ribonucleoprotein D0; D034502:Heterogeneous-Nuclear Ribonucleoprotein D / Q000235:genetics / Q000378:metabolism*; D032383:Myocytes, Cardiac / Q000166:cytology / Q000378:metabolism*; D019255:NADPH Oxidases / Q000235:genetics / Q000378:metabolism; D034622:RNA Interference; D020871:RNA Stability / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D044140:Receptor, Angiotensin, Type 1 / Q000819:agonists / Q000235:genetics / Q000378:metabolism; D017384:Sequence Deletion / Q000235:genetics; D051672:Shal Potassium Channels / Q000096:biosynthesis* / Q000235:genetics; D048051:p38 Mitogen-Activated Protein Kinases / Q000235:genetics / Q000378:metabolism
D020413:3' Untranslated Regions; C000630986:HNRNPD protein, human; D000081035:Heterogeneous Nuclear Ribonucleoprotein D0; D034502:Heterogeneous-Nuclear Ribonucleoprotein D; C000630988:Hnrnpd protein, rat; D044140:Receptor, Angiotensin, Type 1; D051672:Shal Potassium Channels; D000804:Angiotensin II; D019255:NADPH Oxidases; D048051:p38 Mitogen-Activated Protein Kinases
FEBS Lett. 1997 Dec 15;419(2-3):268-70
9428648
Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2543-50
16113063
Circ Res. 2001 Mar 16;88(5):476-82
11249870
Cell Calcium. 2006 Oct;40(4):329-46
16765440
Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H1242-53
17416596
Cardiovasc Res. 1999 May;42(2):270-83
10533566
J Biol Chem. 2003 Aug 29;278(35):33039-48
12819194
Circ Res. 1997 Oct;81(4):533-9
9314834
J Biol Chem. 2003 Jun 6;278(23):20700-7
12668672
J Biol Chem. 1996 Apr 5;271(14):8493-501
8626551
J Biol Chem. 2003 Aug 29;278(35):33029-38
12819195
EMBO J. 2004 Aug 4;23(15):3092-102
15257295
Genomics. 1998 Mar 1;48(2):195-202
9521873
Circ Res. 2006 Apr 28;98(8):1040-7
16556864
Circ Res. 2005 Mar 18;96(5):543-50
15705962
Genes Dev. 1999 Jul 15;13(14):1884-97
10421639
Am J Physiol Heart Circ Physiol. 2006 Sep;291(3):H1183-92
16603688
Mol Cell Biol. 2003 Sep;23(18):6685-93
12944492
Circ Res. 2005 Jun 10;96(11):1208-16
15905459
Cardiovasc Res. 2007 Apr 1;74(1):85-95
17289007